Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2015-12, Vol.5 (12), p.e375-e375
Main Authors: Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Format: Article
Language:English
Subjects:
13/1
13/31
38/77
631/67/1990
631/67/1990/283
Adolescent
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Biomedical and Life Sciences
Biomedicine
Cancer Research
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - physiopathology
Hematology
Humans
Letter to the Editor
Middle Aged
Niacinamide - administration & dosage
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Niacinamide - pharmacokinetics
Oncology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2044-5385
2044-5385
DOI:10.1038/bcj.2015.103